Scott Bizily
Net worth: 85 394 $ as of 31/05/2026
Net worth: 85 394 $ as of 31/05/2026
Scott P.
Bizily is Secretary, Chief Compliance & Legal Officer at 4D Molecular Therapeutics, Inc. since 2024.
Dr. Bizily was General Counsel at Synthego Corp.
from 2019 to 2021.
Dr. Bizily was Director-Corporate Counsel at BioMarin Pharmaceutical, Inc. Dr. Bizily worked at Princeton University from 1991 to 1994.
Dr. Bizily earned a doctorate from the University of Georgia in 2001 and a graduate degree from the University of Pennsylvania in 2005.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/06/2026 | 8,617 ( 0.02% ) | 85 394 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Compliance Officer | 01/12/2021 |
| Companies | Position | End |
|---|---|---|
Synthego Corp.
Synthego Corp. BiotechnologyHealth Technology Develops CRISPR solutions | General Counsel | 01/09/2021 |
| BIOMARIN PHARMACEUTICAL INC. | General Counsel | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Synthego Corp.
Synthego Corp. BiotechnologyHealth Technology Develops CRISPR solutions | Health Technology |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Georgia
University of Georgia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. BiotechnologyHealth Technology Designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions | Health Technology |
Select your edition
All financial news and data tailored to specific country editions